Pay in 4 interest-free payments of $5.97 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
The obesity doctor wanted me to use a weight loss drug
Invest New Drugs 2015;33(2):480489
This tiered sizing structure gives researchers flexibility to match their purchase to their specific protocol requirements without overpaying for product they will not use or running short mid-study
Novo Nordisk's semaglutide (Wegovy) achieved 14.9% weight loss in its landmark STEP 1 trial over 68 weeks a single GLP-1 agonist that first demonstrated the class's potential in obesity
The literature reports that GLP-1 agonists increase excessive enzyme expression and suppress reactive oxygen species (ROS) 73,74
According to current regulatory guidance and platform disclosures, compounded tirzepatide may be available in limited circumstances through certain platforms for patients where prescribers determine a compounded product meets specific clinical needs
